All lobbying filings
Todd Strategy Group
Todd Strategy Group filed a Q3 report for Pfizer Inc. on October 19, 2026, reporting $60,000 in lobbying income.
Lobbying for Pfizer Inc. · Biopharmaceutical company.
Filing · LD-2 quarterly report
Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 19, 2026
Income
$60,000
What the client paid this registrant for the period.
Client based in
District of Columbia
Lobbyists on this filing
3
-
PAUL EDATTELPreviously held: Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg
-
NICHOLAS UEHLECKEPreviously held: Senior Advisor, Dept. of Health and Human Services; Professional Staff/Sr. Legislative Assistant, House Ways and Means Subcommittee
-
NICOLAS MAGALLANESPreviously held: Senior Advisor - House Republican Conference; Policy Advisor/Professional Staff Member - U.S. Representative Lee Terry/Energy and Commerce Committee; Legislative Correspondent/Legislative Aide - U.S. Senator Lamar Alexander
Government bodies contacted
4
Lobbying activity
2
Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification. FDA User Fee Agreements: 2027 PDUFA Cycle. 340B Program Reform. Inflation Reduction Act (IRA). Prior Authorization. Step Therapy Practices. FDA Modernization and Reforms. Drug Pricing. PBM Reform. Vaccine Access and Coverage.
Medicare/Medicaid Issues.